

Michael J Burke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/778252/publications.pdf>

Version: 2024-02-01

72
papers

1,733
citations

304743

22
h-index

302126

39
g-index

72
all docs

72
docs citations

72
times ranked

2784
citing authors

#	ARTICLE	IF	CITATIONS
1	Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. <i>Blood</i> , 2017, 129, 3352-3361.	1.4	236
2	Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2016, 7, 13331.	12.8	218
3	Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. <i>Blood</i> , 2012, 119, 5201-5210.	1.4	123
4	A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed/refractory acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2014, 89, 889-895.	4.1	82
5	Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: A report of the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2015, 62, 743-750.	1.5	63
6	Early Lymphocyte Recovery and Outcomes after Umbilical Cord Blood Transplantation (UCBT) for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 831-840.	2.0	56
7	Oncolytic Seneca Valley Virus: past perspectives and future directions. <i>Oncolytic Virotherapy</i> , 2016, Volume 5, 81-89.	6.0	54
8	Reducing minimal residual disease with blinatumomab prior to HCT for pediatric patients with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 1926-1929.	5.2	53
9	Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27827.	1.5	50
10	Unrelated Cord Blood Transplantation in Adult and Pediatric Acute Lymphoblastic Leukemia: Effect of Minimal Residual Disease on Relapse and Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 963-968.	2.0	48
11	How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. <i>Future Oncology</i> , 2014, 10, 2615-2627.	2.4	46
12	Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131. <i>Cancer</i> , 2018, 124, 1150-1159.	4.1	46
13	Epigenetic Modifications in Pediatric Acute Lymphoblastic Leukemia. <i>Frontiers in Pediatrics</i> , 2014, 2, 42.	1.9	41
14	Impact of Intrathecal Triple Therapy Versus Intrathecal Methotrexate on Disease-Free Survival for High-Risk B-Lymphoblastic Leukemia: Children's Oncology Group Study AALL1131. <i>Journal of Clinical Oncology</i> , 2020, 38, 2628-2638.	1.6	41
15	Differentiating hypersensitivity versus infusion-related reactions in pediatric patients receiving intravenous asparaginase therapy for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 540-551.	1.3	38
16	Severe pegaspargase hypersensitivity reaction rates (grade ≥ 3) with intravenous infusion vs. intramuscular injection: analysis of 54,280 doses administered to 16,534 patients on children's oncology group (COG) clinical trials. <i>Leukemia and Lymphoma</i> , 2018, 59, 1624-1633.	1.3	37
17	Cohesin Mutations in Myeloid Malignancies. <i>Trends in Cancer</i> , 2017, 3, 282-293.	7.4	33
18	Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). <i>Pediatric Blood and Cancer</i> , 2009, 53, 1289-1294.	1.5	32

#	ARTICLE	IF	CITATIONS
19	Decitabine and Vorinostat with Chemotherapy in Relapsed Pediatric Acute Lymphoblastic Leukemia: A TACL Pilot Study. <i>Clinical Cancer Research</i> , 2020, 26, 2297-2307.	7.0	28
20	Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. <i>Leukemia and Lymphoma</i> , 2016, 57, 1938-1941.	1.3	26
21	Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2154-2159.	2.0	25
22	Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG. <i>Haematologica</i> , 2019, 104, 986-992.	3.5	25
23	Levodopa for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature. <i>Leukemia and Lymphoma</i> , 2018, 59, 2360-2368.	1.3	22
24	Experience with ponatinib in paediatric patients with leukaemia. <i>British Journal of Haematology</i> , 2020, 189, 363-368.	2.5	21
25	Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. <i>American Journal of Hematology</i> , 2022, 97, 613-622.	4.1	19
26	Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1943-1948.	1.5	17
27	Desensitization to pegaspargase in children with acute lymphoblastic leukemia and lymphoblastic lymphoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28021.	1.5	17
28	What is the Role of Hematopoietic Cell Transplantation (HCT) for Pediatric Acute Lymphoblastic Leukemia (ALL) in the Age of Chimeric Antigen Receptor T-Cell (CART) Therapy?. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 337-344.	0.6	16
29	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Cancer Discovery</i> , 2021, 11, 1424-1439.	9.4	16
30	Levodopa for pegaspargase-induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia. <i>Cancer Medicine</i> , 2021, 10, 7551-7560.	2.8	14
31	Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232. <i>Leukemia</i> , 2022, 36, 648-655.	7.2	14
32	Epigenetic Therapy in a Patient With Down Syndrome and Refractory Acute Myeloid Leukemia. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, e38-e40.	0.6	13
33	The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. <i>Pediatric Blood and Cancer</i> , 2009, 53, 992-995.	1.5	12
34	A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies. <i>Pediatric Hematology and Oncology</i> , 2020, 37, 465-474.	0.8	12
35	Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences. <i>Future Oncology</i> , 2022, 18, 1285-1299.	2.4	12
36	Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 321-327.	2.0	10

#	ARTICLE	IF	CITATIONS
37	Checkpoint inhibition of PD-L1 and CTLA-4 in a child with refractory acute leukemia. <i>International Journal of Hematologic Oncology</i> , 2019, 8, IJH10.	1.6	9
38	Prognostic impact of minimal residual disease at the end of consolidation in NCI standard-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28929.	1.5	9
39	When Less Is Good, Is None Better? The Prognostic and Therapeutic Significance of Peri-Transplant Minimal Residual Disease Assessment in Pediatric Acute Lymphoblastic Leukemia. <i>Journal of Clinical Medicine</i> , 2017, 6, 66.	2.4	8
40	Isobaric Labeling Strategy Utilizing 4-Plex N^6, N^2 -Dimethyl Leucine (DiLeu) Tags Reveals Proteomic Changes Induced by Chemotherapy in Cerebrospinal Fluid of Children with B-Cell Acute Lymphoblastic Leukemia. <i>Journal of Proteome Research</i> , 2020, 19, 2606-2616.	3.7	7
41	Triple Intrathecal Therapy (Methotrexate/Hydrocortisone/Cytarabine) Does Not Improve Disease-Free Survival Versus Intrathecal Methotrexate Alone in Children with High Risk B-Lymphoblastic Leukemia: Results of Children's Oncology Group Study AALL1131. <i>Blood</i> , 2018, 132, 35-35.	1.4	7
42	Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2019, 134, 3873-3873.	1.4	7
43	Outcomes in children with Down syndrome (DS) and B-lymphoblastic leukemia (B-ALL): A Children's Oncology Group (COG) report. <i>Journal of Clinical Oncology</i> , 2020, 38, 10510-10510.	1.6	7
44	Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group. <i>Blood</i> , 2020, 136, 45-46.	1.4	6
45	Incidence of Allergic Reactions to Pegaspargase (PEG) Administered Intramuscularly Versus Intravenously (IM vs. IV) in Children and Young Adults with High Risk B-Lymphoblastic Leukemia (HR B-ALL): Children's Oncology Group AALL1131. <i>Journal of Clinical Oncology</i> , 2015, 33, 10007-10007.	1.4	6
46	Feasibility of intensive post-Induction therapy incorporating clofarabine (CLOF) in the very high risk (VHR) stratum of patients with newly diagnosed high risk B-lymphoblastic leukemia (HR B-ALL): Children's Oncology Group AALL1131. <i>Journal of Clinical Oncology</i> , 2015, 33, 10007-10007.	1.6	6
47	Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium. <i>Pediatric Blood and Cancer</i> , 2022, 69, .	1.5	6
48	Phase I Study of the Selinexor in Relapsed/Refractory Childhood Acute Leukemia. <i>Blood</i> , 2018, 132, 1405-1405.	1.4	5
49	Invasive Candida Infections in Pediatric Patients Treated on the Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. <i>Blood</i> , 2014, 124, 3650-3650.	1.4	5
50	Pilot Study of Decitabine and Vorinostat with Chemotherapy for Relapsed ALL: A Report from the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. <i>Blood</i> , 2016, 128, 2781-2781.	1.4	5
51	The Genomic Landscape of Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019, 134, 649-649.	1.4	5
52	Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory or High-Risk Leukemias: A Report from the LEAP Consortium. <i>Blood</i> , 2018, 132, 261-261.	1.4	3
53	Emerging immunotherapy in pediatric lymphoma. <i>Future Oncology</i> , 2016, 12, 257-270.	2.4	2
54	Allogeneic Hematopoietic Cell Transplantation Provides No Benefit for Patients With Hypodiploid Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2019, 37, 763-764.	1.6	2

#	ARTICLE	IF	CITATIONS
55	Novel germline TRAF3IP3 mutation in a dyad with familial acute B lymphoblastic leukemia. <i>Cancer Reports</i> , 2021, 4, e1335.	1.4	2
56	The UK ALLR3 Chemotherapy Regimen for Relapsed/Refractory Acute Lymphoblastic Leukemia of Childhood: A Multi-Institutional Retrospective Study of Treatment Related Adverse Events. <i>Blood</i> , 2014, 124, 3647-3647.	1.4	2
57	Enhanced Risk Stratification of 21,178 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia (ALL) Incorporating White Blood Count (WBC), Age, and Minimal Residual Disease (MRD) at Day 8 and 29 As Continuous Variables: A Children's Oncology Group (COG) Report. <i>Blood</i> , 2020, 136, 39-40.	1.4	2
58	Treatment of a CNS relapse while on therapy for Burkitt lymphoma. <i>Pediatric Blood and Cancer</i> , 2009, 52, 290-292.	1.5	1
59	Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group. <i>Pediatric Hematology and Oncology</i> , 2017, 34, 355-364.	0.8	1
60	Correlation of Lymphocyte Count with Treatment Response to Tyrosine Kinase Inhibitors in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase. <i>Blood</i> , 2014, 124, 4538-4538.	1.4	1
61	Phase 1 Study of Decitabine and Vorinostat Followed By Fludarabine, Cytarabine and G-CSF (FLAG) in Children, Adolescents and Young Adults with Relapsed/Refractory AML: Report from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium. <i>Blood</i> , 2019, 134, 1325-1325.	1.4	1
62	Phase 1b Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL). <i>Blood</i> , 2021, 138, 1235-1235.	1.4	1
63	Outcomes of Patients with Down Syndrome and CRLF2-Overexpressing Acute Lymphoblastic Leukemia (ALL): A Report from the Children's Oncology Group (COG). <i>Blood</i> , 2020, 136, 44-45.	1.4	1
64	Prognostic Impact of CNS-2 status in T-ALL: A report from the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2021, 39, 10003-10003.	1.6	0
65	Higher CSA Levels After Umbilical Cord Blood Transplant For Acute Leukemia Result In Improved Survival. <i>Blood</i> , 2013, 122, 2097-2097.	1.4	0
66	Deciphering the Epigenetic Landscape of Relapsed Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 612-612.	1.4	0
67	The Role of Hematopoietic Stem-Cell Transplantation in First Remission in Pediatric Acute Lymphoblastic Leukemia: A Narrative Review. <i>Journal of Pediatrics Review</i> , 2017, 5, .	0.3	0
68	Whole Genome Bisulfite Sequencing (WGBS) Robustly Measures the Pharmacodynamic Effect of Decitabine/Vorinostat Epigenetic Treatment in Relapsed Pediatric ALL Demonstrating Potent Hypomethylation Associated with Upregulation of PRC2 and TP53 Targets. <i>Blood</i> , 2018, 132, 918-918.	1.4	0
69	Outcome in Adolescent and Young Adult (AYA) Patients Compared to Younger Patients Treated for High-Risk B-Lymphoblastic Leukemia (HR B-ALL): Report from the Children's Oncology Group Study AALL0232. <i>Blood</i> , 2019, 134, 286-286.	1.4	0
70	Comparison of chemotherapy dose intensity for AYAs on COG AALL1131 versus CALGB 10403. <i>Journal of Clinical Oncology</i> , 2020, 38, 10520-10520.	1.6	0
71	Comparison of Current and Enhanced Risk Stratification of 21,199 Children, Adolescents, and Young Adults with Acute Lymphoblastic Leukemia Using Objective Risk Categorization Criteria: A Children's Oncology Group Report. <i>Blood</i> , 2021, 138, 2382-2382.	1.4	0
72	Novel Germline TRAF3IP3 Mutation in a Dyad with Familial Acute B Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 20-20.	1.4	0